Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis英文电子书.pdf

British Journal of Cancer (2010) 103, 391 – 400 2010 Cancer Research UK All rights reserved 0007 – 0920/10 Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis 1,6 1,6,7 2 3 4 1 5 2 *,1 A Xue , CJ Scarlett , L Chung , G Butturini , A Scarpa , R Gandy , SR Wilson , RC Baxter and RC Smith 1 2 Department of Surgery, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia; Kolling Institute of Medical 3 Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia; Surgical and Anaesthesiological Department, 4 University of Verona, Piazzale La Scuro, Verona 1037134, Italy; Pathology Department, University of Verona, Piazzale La Scuro, Verona 1037134, Italy; 5Mathematical Sciences Institute, Australian National University, Canberra, Australian Capital Territory 0200, Australia BACKGROUND AND AIMS: The serum/plasma proteome was explored for biomarkers to improve the diagnostic ability of CA19-9 in pancreatic adenocarcinoma (PC). METHODS: A Training Set of serum samples from 20 resectable and 18 stage IV PC patients, 54 disease controls (DCs) and 68 healthy volunteers (HVs) were analysed by surface-enhanced laser desorption and ionisation time-of-flight mass spectrometry (SELDI-TOF MS). The resulting protein panel was validated on 40 resectable PC, 21 DC and 19 HV plasma samples (Validation-1 Set) and further by